A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

The UK’s drug regulator has cleared a higher-strength dose of the weight-loss injection Wegovy, as demand for the treatment is expected to rise sharply. The newly approved 7.2 mg dose is three times stronger than the current weekly dose of 2.4 mg. The Medicines and Healthcare products Regulatory Agency, or MHRA, said the stronger dose can lead to weight loss of more than 20 per cent. Trial data reviewed by the regulator showed that around one in three adults living with obesity who took the higher weekly dose lost more than 25 per cent of their body weight after 72 weeks.

Weight Loss Jab To Launch Stronger Dosage In UK

The approval comes alongside research from the University of Oxford suggesting that people using drugs such as semaglutide, sold as Wegovy, and tirzepatide, marketed as Mounjaro, tend to lose weight while on treatment but regain it within about 20 months after stopping the injections. According to The Independent, people who lose weight through diet and exercise tend to maintain the loss for longer, close to four years on average, although some regain still occurs over time.

Researchers cautioned that people using weight-loss injections need long-term support, as their analysis showed weight returns more quickly after stopping the drugs than it does for those following traditional diet plans. The study also found that improvements in blood sugar, cholesterol levels, and blood pressure fade once the medication is discontinued, leaving many patients back where they started. The Oxford-led research, published in the British Medical Journal, reviewed 37 studies involving more than 9,000 participants.

What Is Wegovy?

Wegovy is a widely used weight-loss injection containing the active ingredient semaglutide. Studies show that people on the standard maintenance dose of 2.4 mg lose an average of 17 per cent of their body weight over 68 weeks. A higher 7.2 mg dose has now been approved for use in the UK, with clinical trials indicating it can deliver weight loss of up to 21 per cent.

What is Wegovy 7.2mg?

Wegovy 7.2 mg is a new maintenance dose of the semaglutide-based weight-loss injection. Until now, the highest approved weekly dose was 2.4 mg. The stronger 7.2 mg option is being introduced by the drug’s manufacturer, Novo Nordisk, following its submission to regulators for approval.

This new dose uses the same active ingredient, semaglutide, and works in the same way by helping overweight or obese adults lose weight. It does this by copying the action of the hormone glucagon-like peptide-1, or GLP-1, which helps regulate appetite and food intake.

Further studies examining the safety and effectiveness of the higher dose are already in progress. The latest findings from the STEP UP phase 3b trial were published in November 2025.

How Effective Is The Wegovy 7.2 Dose?

The STEP UP phase 3b trial assessed how safe and effective the 7.2 mg dose of Wegovy is. The study included 1,407 participants who were randomly assigned to receive either 7.2 mg or 2.4 mg of Wegovy, or a placebo, over an 11-month period.

The average weight loss recorded was:

• 20.7 per cent in the 7.2 mg group
• 17.5 per cent in the 2.4 mg group
• 2.4 per cent among those given a placebo

The approval follows recent findings showing that about 1.6 million people used Wegovy or Mounjaro last year. Another 3.3 million people said they would consider using weight-loss medications in the coming year.

According to The Independent, research by University College London based on a survey of 5,260 people found that 2.9 per cent of respondents were using GLP-1 drugs for weight loss. Of those, 15 per cent were taking medication that is not licensed for that purpose. Researchers warned that using drugs off label, meaning for conditions they are not approved to treat, such as using diabetes drugs for weight loss, can carry safety risks if taken without proper medical supervision.

The Upstate South Carolina measles outbreak grew to 434 confirmed cases by Tuesday, officials reported. Health authorities said the outbreak has expanded quickly, with 124 new cases recorded in just a few days between January 9 and January 13, 2026.

According to the South Carolina Department of Public Health, around 409 people were placed under quarantine and 17 were kept in isolation as of Tuesday. Officials also confirmed that one individual, unaware they were contagious at the time, visited the South Carolina State Museum in Columbia on January 2 between 1 pm and 5 pm. Anyone who was at the museum during that window may have been exposed and has been advised to watch closely for symptoms.

What Is Measles?

Measles, also known as rubeola, is a highly contagious viral illness that typically causes fever, cough, runny nose, red eyes, and a widespread red rash. It spreads through airborne droplets released when an infected person coughs or sneezes. The virus is extremely infectious and can remain in the air or on surfaces for up to two hours.

While some cases are mild, measles can lead to serious complications such as pneumonia, swelling of the brain, and even death, especially in young children. A safe and effective vaccine has prevented millions of deaths worldwide, but outbreaks continue to occur in areas with low vaccination coverage, according to the Mayo Clinic.

Measles Cases Spreading In The US

South Carolina health officials said yesterday that the state’s measles count has reached 434 after confirming 124 new cases. At present, 409 residents are in quarantine and 17 are in isolation, with some quarantine periods expected to last until February 6.

Mobile vaccination units are operating this week, and officials are strongly encouraging residents to get vaccinated. “Getting vaccinated now can help people avoid long periods of quarantine at home after exposure to the measles virus. Vaccination within 72 hours of exposure can prevent measles infection,” the state’s department of public health said in its latest update.

Measles Symptoms

Measles can result in hospitalization and, in severe cases, death. Common symptoms include:

• High fever, which can rise above 104 degrees
• Cough
• Runny nose
• Red, watery eyes
• Tiny white spots inside the cheeks, gums, and on the roof of the mouth known as Koplik spots, appearing two to three days after symptoms begin
• A red, raised, blotchy rash that usually starts on the face and spreads to the trunk, arms, and legs within three to five days after symptoms start

Measles Vaccine Prevention

According to the US Centers for Disease Control and Prevention, the measles, mumps, and rubella or MMR vaccine is 97 percent effective against measles and 86 percent effective against mumps when both recommended doses are received.

The MMR vaccine is part of the routine childhood immunization schedule. The first dose is typically given between 12 and 15 months of age, followed by a second dose between ages 4 and 6. Children who are traveling internationally may receive the vaccine earlier.

As reported by CIDRAP, South Carolina allows religious exemptions from vaccination through a notarized form, without requiring a doctor’s approval. One of the schools linked to the early phase of the outbreak, Global Academy of South Carolina, reported a vaccination rate of just 17 percent during the 2024 to 25 school year.

Of the 434 measles cases tracked over the past six months, 378 patients were unvaccinated and 47 had an unknown vaccination status. Only six people were fully vaccinated, while three had received partial vaccination. About two thirds of all measles cases in South Carolina involve children and teens aged 5 to 17, accounting for 287 cases.

US Health and Human Services Secretary Robert F. Kennedy, Jr. has canceled nearly $2billion worth of funding for substance abuse and mental health programs across the country in a sweeping decision.

The MAHA leader dissolved 2,000 Substance Abuse and Mental Health Services Administration (SAMHSA) related-grants overnight, a move that many experts say will hamper frontline care for some of the most vulnerable people in the country.

These grants provide resources for overdose prevention, addiction recovery and mental health services to individuals, regardless of age and gender.

“Without that funding, people are going to lose access to lifesaving services,” Yngvild Olsen, former director of SAMHSA’s Center for Substance Abuse Treatment and a national adviser at Manatt Health, said.

According to letters sent to multiple non-profits associated with the SAMHSA, grants are terminated as of January 13 and "costs resulting from financial obligations incurred after termination are not allowable", NPR revealed.

This move comes on top of deep Medicaid cuts, passed last year by the Republican-dominated Congress, which has severely affected numerous mental health and addiction care providers.

Why Were The Grants Canceled?

While officials say that the grants were reinstated the next morning, affected organizations claim to have received no such notice and have begun to make difficult decisions in response to the cuts, including laying off employees and canceling scheduled trainings, according to AP.

What Are Experts Saying?

Advocacy groups across the nation are now amplifying concerns over the abrupt cancellation of federal mental health and substance use grants. National Alliance on Mental Illness (NAMI) CEO Daniel H. Gillison Jr noted: "These cuts are disheartening and cruel, and they threaten the life-saving work of hundreds of organizations that provide critical mental health support across the United States.

"Addressing our mental health and substance use crises in this country has never been political, which is why it continues to have bipartisan support in Congress. These abrupt and unjustified cuts will immediately disrupt suicide prevention efforts, family and peer recovery support, overdose prevention and treatment and mental health awareness and education programming, along with so many more essential services, putting an unknown number of lives at stake.

"These aren't just numbers on paper. These are decisions that have real and harmful consequences for millions of people and communities around the country."

Robert Franks, CEO of the Boston-based mental health provider the Baker Center for Children and Families, added that loss of funding would force his organization to lay off staff and put care in jeopardy for some 600 families receiving it.

What Does Congress Say?

"These cuts will cost lives. Throughout his tenure, Secretary Kennedy has done nothing to make Americans safer, and everything to place us in more danger. Restricting vaccine access, calling into question proven treatments for diseases, and now stripping communities of the resources they need to prevent drug overdoses and treat addiction.

"These cuts by the Trump Administration are senseless and unconscionable. They will destroy families, ruin lives and cause preventable deaths. The Trump Administration must immediately reverse these cancellations of critical grants so that American families can continue to receive the services they depend on to survive."